



(51) International Patent Classification:

A61K 31/437 (2006.01) A61P 35/00 (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2024/054695

(22) International Filing Date:

06 November 2024 (06.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/547,654 07 November 2023 (07.11.2023) US
63/641,293 01 May 2024 (01.05.2024) US
63/704,371 07 October 2024 (07.10.2024) US

(71) Applicant: **TREELINE BIOSCIENCES, INC.** [US/US];
500 Arsenal Street, Watertown, Massachusetts 02472 (US).

(72) Inventors: **HORN, Evan J.**; 11180 Roselle Street, Suite A,
San Diego, California 92121 (US). **HANSEN, Joshua D.**;
11180 Roselle Street, Suite A, San Diego, California 92121
(US). **ALEXANDER, Matthew D.**; 11180 Roselle Street,
Suite A, San Diego, California 92121 (US). **HUANG, Fei**;
11180 Roselle Street, Suite A, San Diego, California 92121
(US). **NAGY, Mark A.**; 11180 Roselle Street, Suite A, San
Diego, California 92121 (US). **ZAHARA, Adam Jamil**;
11180 Roselle Street, Suite A, San Diego, California 92121
(US).

(74) Agent: **KENDALL, John T.** et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with amended claims (Art. 19(1))

(54) Title: TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-X_L DEGRADERS

(57) Abstract: This disclosure provides compounds of Formula (I) (e.g., Formula (I-1) (e.g., Formula (I-a1), (I-a3), (I-b1), (I-bb1), (I-d1), (I-dd1), (I-e1), (I-e1-a), (I-f1), (I-g1), (I-b3), (I-c3), (I-d3), or (I-e3)), Formula (I-2) (e.g., Formula (I-a2), (I-a4), (I-b2), (I-c2), (I-d2), (I-e2), (I-b4), (I-c4), or (I-e4)), Formula (I-5) (e.g., (I-a5), (I-b5), or (I-e5)), Formula (I-6) (e.g., (I-a6), (I-b6), or (I-c6)), Formula (II-1), or Formula (II-2)) or Formula (A), or a pharmaceutically acceptable salt thereof, that induce degradation of a BCL-X_L protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions comprising the compounds, or pharmaceutically acceptable salts thereof, provided herein as well as methods of using and making the same.